Antiplatelet agents for the treatment of adults with COVID-19

CONCLUSIONS: In people with confirmed or suspected COVID-19 and moderate to severe disease, we found moderate-certainty evidence that antiplatelets probably result in little to no difference in 28-day mortality, clinical worsening or improvement, but probably result in a slight reduction in thrombotic events. They probably increase the occurrence of major bleeding events. Low-certainty evidence suggests that antiplatelets may result in a slight increase in serious adverse events. In people with confirmed COVID-19 and mild symptoms, we found low-certainty evidence that antiplatelets may result in little to no difference in 45-day mortality and serious adverse events, and may slightly reduce thrombotic events. The effects on the combined outcome admission to hospital or death up to day 45 and major bleeding events are very uncertain. Quality of life was not reported. Included studies were conducted in high- to lower middle-income settings using antiplatelets prior to vaccination roll-outs. We identified a lack of evidence concerning quality of life assessments, adverse events and people with asymptomatic infection. The 14 ongoing and three completed, unpublished RCTs that we identified in trial registries address similar settings and research questions as in the current body of evidence. We expect to incorporate the findings of these studies in future versions of this review.PMID:37489818 | PMC:PMC10368416 | DOI:10.1002/14651858.CD015078

Source: Pain Physician - July 25, 2023 Category: Anesthesiology Authors: Anna-Lena Fischer Sarah Messer Rachel Riera Ana Luiza C Martimbianco Miriam Stegemann Lise J Estcourt Stephanie Weibel Ina Monsef Marike Andreas Rafael L Pacheco Nicole Skoetz Source Type: research